HDAC9 and pulmonary fibrosis: Preclinical studies of the related pan-HDAC inhibitor SAHA in the mouse model of bleomycin-induced lung fibrosis demonstrated significant attenuation of development of pulmonary fibrosis and improvement of lung function in mice [33].